Understanding mode of action can drive the translational pipeline towards more reliable health benefits for probiotics

Michiel Kleerebezem*, Sylvie Binda, Peter A. Bron, Gabriele Gross, Colin Hill, Johan E.T. van Hylckama Vlieg, Sarah Lebeer, Reetta Satokari, Arthur C. Ouwehand

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

8 Citations (Scopus)

Abstract

The different levels of knowledge described in a translational pipeline (the connection of molecular mechanisms with pre-clinical physiological and human health effects) are not complete for many probiotics. At present, we are not in a position to fully understand the mechanistic basis of many well established probiotic health benefits which, in turn, limits our ability to use mechanisms to predict which probiotics are likely to be effective in any given population. Here we suggest that this concept of a translation pipeline connecting mechanistic insights to probiotic efficacy can support the selection and production of improved probiotic products. Such a conceptual pipeline would also provide a framework for the design of clinical trials to convincingly demonstrate the benefit of probiotics to human health in well-defined subpopulations.

Original languageEnglish
Pages (from-to)55-60
JournalCurrent Opinion in Biotechnology
Volume56
DOIs
Publication statusPublished - 1 Apr 2019

Fingerprint

Probiotics
Insurance Benefits
Pipelines
Health
Clinical Trials
Population

Cite this

Kleerebezem, Michiel ; Binda, Sylvie ; Bron, Peter A. ; Gross, Gabriele ; Hill, Colin ; van Hylckama Vlieg, Johan E.T. ; Lebeer, Sarah ; Satokari, Reetta ; Ouwehand, Arthur C. / Understanding mode of action can drive the translational pipeline towards more reliable health benefits for probiotics. In: Current Opinion in Biotechnology. 2019 ; Vol. 56. pp. 55-60.
@article{79f91b0323864212a11609d72735f7b4,
title = "Understanding mode of action can drive the translational pipeline towards more reliable health benefits for probiotics",
abstract = "The different levels of knowledge described in a translational pipeline (the connection of molecular mechanisms with pre-clinical physiological and human health effects) are not complete for many probiotics. At present, we are not in a position to fully understand the mechanistic basis of many well established probiotic health benefits which, in turn, limits our ability to use mechanisms to predict which probiotics are likely to be effective in any given population. Here we suggest that this concept of a translation pipeline connecting mechanistic insights to probiotic efficacy can support the selection and production of improved probiotic products. Such a conceptual pipeline would also provide a framework for the design of clinical trials to convincingly demonstrate the benefit of probiotics to human health in well-defined subpopulations.",
author = "Michiel Kleerebezem and Sylvie Binda and Bron, {Peter A.} and Gabriele Gross and Colin Hill and {van Hylckama Vlieg}, {Johan E.T.} and Sarah Lebeer and Reetta Satokari and Ouwehand, {Arthur C.}",
year = "2019",
month = "4",
day = "1",
doi = "10.1016/j.copbio.2018.09.007",
language = "English",
volume = "56",
pages = "55--60",
journal = "Current Opinion in Biotechnology",
issn = "0958-1669",
publisher = "Elsevier",

}

Understanding mode of action can drive the translational pipeline towards more reliable health benefits for probiotics. / Kleerebezem, Michiel; Binda, Sylvie; Bron, Peter A.; Gross, Gabriele; Hill, Colin; van Hylckama Vlieg, Johan E.T.; Lebeer, Sarah; Satokari, Reetta; Ouwehand, Arthur C.

In: Current Opinion in Biotechnology, Vol. 56, 01.04.2019, p. 55-60.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Understanding mode of action can drive the translational pipeline towards more reliable health benefits for probiotics

AU - Kleerebezem, Michiel

AU - Binda, Sylvie

AU - Bron, Peter A.

AU - Gross, Gabriele

AU - Hill, Colin

AU - van Hylckama Vlieg, Johan E.T.

AU - Lebeer, Sarah

AU - Satokari, Reetta

AU - Ouwehand, Arthur C.

PY - 2019/4/1

Y1 - 2019/4/1

N2 - The different levels of knowledge described in a translational pipeline (the connection of molecular mechanisms with pre-clinical physiological and human health effects) are not complete for many probiotics. At present, we are not in a position to fully understand the mechanistic basis of many well established probiotic health benefits which, in turn, limits our ability to use mechanisms to predict which probiotics are likely to be effective in any given population. Here we suggest that this concept of a translation pipeline connecting mechanistic insights to probiotic efficacy can support the selection and production of improved probiotic products. Such a conceptual pipeline would also provide a framework for the design of clinical trials to convincingly demonstrate the benefit of probiotics to human health in well-defined subpopulations.

AB - The different levels of knowledge described in a translational pipeline (the connection of molecular mechanisms with pre-clinical physiological and human health effects) are not complete for many probiotics. At present, we are not in a position to fully understand the mechanistic basis of many well established probiotic health benefits which, in turn, limits our ability to use mechanisms to predict which probiotics are likely to be effective in any given population. Here we suggest that this concept of a translation pipeline connecting mechanistic insights to probiotic efficacy can support the selection and production of improved probiotic products. Such a conceptual pipeline would also provide a framework for the design of clinical trials to convincingly demonstrate the benefit of probiotics to human health in well-defined subpopulations.

U2 - 10.1016/j.copbio.2018.09.007

DO - 10.1016/j.copbio.2018.09.007

M3 - Article

VL - 56

SP - 55

EP - 60

JO - Current Opinion in Biotechnology

JF - Current Opinion in Biotechnology

SN - 0958-1669

ER -